Navigation Links
CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Advanced Breast Cancer
Date:6/17/2009

- 12 week progression free rate supports advancement into second stage of Simon 2-Stage designed trial -

BRANFORD, Conn., June 17 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) announced today that its Phase I/II Trial evaluating CR011-vcMMAE for the treatment of patients with advanced breast cancer has met the efficacy criteria for advancement to the second stage of enrollment. To date, 29 patients have been enrolled in this trial, including 15 in the Phase II portion. Two of the first four evaluable Phase II patients were progression-free at 12 weeks, therefore, as part of the Simon 2-Stage design, the Phase II trial will now advance to the second stage and enroll a total of approximately 25 patients. The principal investigator of the study is Dr. Linda Vahdat, Medical Director of the Breast Cancer Research Program and Associate Professor of Clinical Medicine, /Weill Cornell. CuraGen anticipates presenting updated results from this study during the second half of 2009.

About CR011-vcMMAE

CR011-vcMMAE is an antibody-drug conjugate (ADC) being developed by CuraGen that consists of a fully-human monoclonal antibody, CR011, linked to a potent cell-killing drug, monomethyl-auristatin E (MMAE). The ADC technology, comprised of MMAE and a stable linker system for attaching it to CR011, was licensed from Seattle Genetics, Inc. The ADC is designed to be stable in the bloodstream. Following intravenous administration, CR011-vcMMAE targets and binds to GPNMB, a specific protein that is predominantly expressed on the surface of cancer cells, including melanoma, breast cancer and glioma. Upon internalization by the targeted cell, CR011-vcMMAE is designed to release MMAE from CR011 to produce a cell-killing effect. CR011-vcMMAE is currently in two Phase II trials assessing its safety and efficacy in the
'/>"/>

SOURCE CuraGen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. CuraGen Updates CR011-vcMMAE Data at ASCO
2. CuraGen to Present CR011-vcMMAE Data at ASCO
3. CuraGen Announces Preliminary Data from Ongoing Phase II Study Showing Clinical Activity of CR011-vcMMAE in Patients with Metastatic Melanoma
4. CuraGen to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and CR011-vcMMAE Phase II Trial Results on November 3, 2008
5. CuraGen Completes Enrollment in Phase II Trial of CR011-vcMMAE in Metastatic Melanoma
6. CuraGen Reports Second Quarter 2008 Financial Results and Clinical Progress of CR011-vcMMAE
7. CuraGen Announces Initiation of Phase II Trial of CR011-vcMMAE in Patients with Advanced Breast Cancer
8. CuraGen Announces Expansion of CR011-vcMMAE Phase II Trial in Melanoma
9. CuraGen Announces Data From Ongoing Phase I/II Trial Showing Clinical Activity of CR011-vcMMAE in Metastatic Melanoma
10. CuraGen Advances CR011-vcMMAE into Phase II
11. CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014 Research and Markets  has announced ... by Product, Component, Application and Geography - Global Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 ... witness a moderate growth as the markets of the ... reached the saturation levels. The demand is expected to ...
(Date:7/24/2014)... -- "North America Orthopedic Braces and Supports Market Outlook ... America Orthopedic Braces and Supports market. The report provides ... units) and average price data (in US dollars), within ... , Ankle Braces and Supports , Spinal ... Supports. Photo - http://photos.prnewswire.com/prnh/20140723/129806 ...
(Date:7/24/2014)...   Royal Philips (NYSE: PHG ... 510(k) clearance from the U.S. Food and Drug Administration ... in the U.S. VISIQ is the first ... mobility, performance and simplicity into a single miniaturized solution, ... more OB patients. This breakthrough ultrasound device ...
Breaking Medicine Technology:Machine Health Monitoring (Vibration Monitoring, Thermography, Ultrasound Emission, Lubricating Oil Analysis, Corrosion Monitoring, Motor Current Signature Analysis) Market - Forecast to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 2North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 3North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 4North America Orthopedic Braces and Supports Market (Knee, Ankle & Spinal Braces) to 2020 5Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 2Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system 3
... Inc. (NASDAQ: MSON ), a medical ... therapeutic ultrasonic products worldwide for wound debridement, spinal ... surgical and medical applications, has entered into a ... Instrument Co., Ltd., based in Taichung, Taiwan, R.O.C., ...
... 3, 2011 A new type of radiation therapy ... University Hospital that cuts down on treatment time while ... patient undergoes a lumpectomy to remove a cancerous tumor, ... can take an average of five weeks. But using ...
Cached Medicine Technology:Misonix Announces New Distribution Agreement for Taiwan 2Misonix Announces New Distribution Agreement for Taiwan 3SIUH Offers New 5-Day Breast Cancer Therapy 2
(Date:7/24/2014)... -- A new formulation of a powerful narcotic painkiller ... drug has been approved by the U.S. Food and ... Purdue Pharma, the pill is a combination of the ... euphoric effects of oxycodone. The naloxone is only activated ... according to the FDA. While Targiniq has only ...
(Date:7/24/2014)... Annual National Venous Interventional Summit is available at: ... established Venous Endovascular Interventional Strategies group comprised of ... to provide a "How To" meeting for cardiologists ... advancing their knowledge and skills in venous interventions ... comprehensive venous interventional program. Topics at this year,s ...
(Date:7/24/2014)... ACRIA & AMIDA CARE TO COHOST WHITE HOUSE ONAP ... the Dates: August 7th & August 8th* , ... for Life” forums this August, led by Douglas Brooks, the ... AIDS Policy (ONAP). This will be a wonderful opportunity to ... organizations, consumers and advocates to advance the National HIV/AIDS Strategy ...
(Date:7/24/2014)... 24, 2014 National Analysts Worldwide, the ... it will operate globally under the name, NAXION ... woman-owned Employee Stock Ownership Plan (ESOP) organization led by ... Ph.D . The firm guides market strategy in ... , Said McDonald, “We wanted our name to ...
(Date:7/24/2014)... For the first time in her career, Susan ... singer first became a known musical commodity after appearing on the ... the show was “I Dreamed a Dream,” from Les Misérables and ... since her time on the reality show in 2009 and now ... American fans. The tour will kick off on October 8 at ...
Breaking Medicine News(10 mins):Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 3Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 2Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 4
... WASHINGTON, Sept. 18 Americans believe that,providing medical care ... top of our nation,s priorities, in line with resolving ... a new nationwide survey. What,s,more, three-quarters of the public ... military veterans., And what do Americans think should ...
... identified specific damages to the brain that may occur when ... study in mice found that those animals that lived alone ... more damage to neurons in one part of the brain ... studies in humans have shown that socially isolated heart attack ...
... primarily for blind people places a layer of information technology ... interest along their path as they pass them. , The ... of Michigan. Researchers will present their work at two conferences ... A to point B. They learn to count steps if ...
... is almost always adenocarcinoma or signet ring cell carcinoma ... cell carcinoma. We report a patient with adenocarcinoma of ... This is the first reported case of gastric cancer ... to be published on 28 May 2008 in the ...
... numerous randomized clinical trials (RCT) have evaluated, and ... treatment regimens. Surgery remains standard care for early ... have also shown a survival benefit associated with ... patterns of care for these cancers. A study ...
... Introduced, MINNEAPOLIS, Sept. 17 Today ClearWay ... Board Members and,thanked outgoing members for their service ... and Executive Director of the Honeywell,Foundation as well ... affairs for Honeywell, was elected as the new ...
Cached Medicine News:Health News:Survey Shows Most Americans Want Government to Stand Up for Veterans 2Health News:Survey Shows Most Americans Want Government to Stand Up for Veterans 3Health News:Study suggests why heart attack victims do better with social support 2Health News:Study suggests why heart attack victims do better with social support 3Health News:New Bluetooth system orients blind and sighted pedestrians 2Health News:New Bluetooth system orients blind and sighted pedestrians 3Health News:How to treat gastroesophageal adenocarcinom patients? 2Health News:ClearWay Minnesota(SM) Board Approves New Officers 2Health News:ClearWay Minnesota(SM) Board Approves New Officers 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: